LAKE BLUFF, Ill.--(BUSINESS WIRE)--NeoPharm, Inc. (Other OTC: NEOL.PK) today announced the results of a Phase I clinical trial of Liposome Encapsulated Docetaxel (LE-DT) an active component of Taxotere® at a joint International Conference of the American Association for Cancer Research (AACR), the National Cancer Institute (NCI) and the European Organization for Research and Treatment of Cancer (EORTC) being held in Boston, MA. This multicenter, open label dose escalation trial of LE-DT was performed at Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC and Scottsdale Clinical Research Institute/TGEN, Scottsdale, AZ.
